Structure via PubChem · Public domain (PubChem)
atagabalin
Sign in to saveAtagabalin (, ; developmental code name PD-0200390) is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α2δ calcium channels (1 and 2). It was under development as a treatment for insomnia, but was discontinued following unsatisfactory trial results. The drug reached phase 2 clinical trials for this indication prior to the discontinuation of its development.
Chemical data
- Formula
- C10H19NO2
- Molecular weight
- 185.26 g/mol
- IUPAC name
- 2-[(3S,4S)-1-(aminomethyl)-3,4-dimethylcyclopentyl]acetic acid
- SMILES
- C[C@H]1CC(C[C@@H]1C)(CC(=O)O)CN
- InChIKey
- IUVMAUQEZFTTFB-YUMQZZPRSA-N
- XLogP
- -1.3
- Polar surface area
- 63.3 Ų
- H-bond donors
- 2
- H-bond acceptors
- 3
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 2
- Molecule type
- Small molecule
- Indications
- insomnia
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 185.142
Show 3 more facts
- chemical formula
- C₁₀H₁₉NO₂
- canonical SMILES
- CC1CC(CC1C)(CC(=O)O)CN
- isomeric SMILES
- C[C@H]1CC(C[C@@H]1C)(CC(=O)O)CN
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
Atagabalin (, ; developmental code name PD-0200390) is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α2δ calcium channels (1 and 2). It was under development as a treatment for insomnia, but was discontinued following unsatisfactory trial results. The drug reached phase 2 clinical trials for this indication prior to the discontinuation of its development.
==See also== List of investigational insomnia drugs 4-Methylpregabalin Gabapentin enacarbil PD-217,014 PD-0299685
Excerpted from Wikipedia’s “atagabalin” article, available under the CC BY-SA 4.0 licence.